Optimizing Emergency Department Care for People With Bleeding Disorders: A Scoping Review of Barriers and Interventions for Improvement Authors: Ling‐Yi Guo, Diane L. Lorenzetti, Natalia Rydz, Dawn Goodyear, Julia Hews‐Girard, Garrick Mok, Roy Khalife, Kelsey Uminski Published: 2026 ABSTRACT ABSTRACTBackgroundEmergency department (ED) care is critical for managing acute bleeding events in people with bleeding disorders. Despite international guidelines recommending haemostatic treatment within 30–60 min, delays and deviations from best practices are common and associated with poorer outcomes.ObjectiveIdentify barriers to guideline‐concordant ED management of bleeding disorders, evaluate interventions, assess clinical impact, and highlight knowledge gaps to inform future research.MethodsFive databases (MEDLINE, Embase, Scopus, Web of Science, Cochrane Library) were searched from inception to 21 March 2025, following established scoping review guidelines and a pre‐registered protocol. Eligible studies examined barriers or interventions for improving ED care. Data were independently screened and extracted by two reviewers, then synthesized using descriptive statistics and narrative synthesis.ResultsSeventeen studies out of 3541 met inclusion criteria. Common barriers included electronic medical record (EMR) limitations, absence of standardized protocols, limited healthcare professional education, and inadequate communication with haematology. Delayed time to therapy (n = 8, range 1.4–5.6 h) was frequently reported; additional impacts included failure to administer haemostatic therapy for confirmed/suspected bleeding, non‐indicated diagnostic testing, and patient mortality. Most interventions combined EMR enhancements with education. All interventions were associated with improved outcomes, including reduced time to therapy (n = 4, range 0.4–2.5 h). Perspectives of people with bleeding disorders and caregivers were infrequently incorporated.ConclusionThis review provides the first comprehensive synthesis of barriers and interventions in ED care for people with bleeding disorders, identifying critical gaps in timely treatment, interdisciplinary coordination, and stakeholder engagement. These findings provide a foundation for future quality improvement research. Introduction Emergency department (ED) care is critical for people with bleeding disorders, who are at higher risk of acute spontaneous or traumatic musculoskeletal, internal organ, central nervous system, and mucocutaneous bleeding [1]. For people unable to self‐infuse or without access to haemophilia treatment centres (HTCs), as well as those who experience severe bleeding events, the ED often serves as the primary site of acute care [2]. Although international guidelines recommend haemostatic therapy within 30–60 min of presentation to ED based on clinical suspicion, delayed administration, incorrect dosing, and lack of therapy continue to occur [3, 4]. Delays or errors in haemostatic therapy are associated with increased morbidity and mortality, long‐term complications, prolonged hospitalization, and substantial healthcare costs [3, 5]. The challenges of delivering timely ED care are compounded by broader system pressures, including overcrowding, high patient volumes, competing clinical priorities, and the absence of standardized protocols [6, 7, 8, 9, 10]. Limited ED clinical exposure to bleeding disorders, coupled with complex and variable presentations, can further impact recognition of bleeding events and timely management [6, 9, 10, 11]. These intersecting system‐, healthcare professional‐ (HCP), workflow‐, and patient‐level factors underscore the complexity of achieving optimal ED management. In the absence of an integrated synthesis of this literature, efforts to improve ED care are fragmented and insufficiently informed by prior evidence. Given the breadth and heterogeneity of the available evidence, we conducted a scoping review to characterize barriers and interventions across multiple levels of the care pathway, and highlight priorities for future research to inform improvements in clinical practice and patient outcomes. Methods Study Design We followed the Arksey and O'Malley framework for conducting scoping reviews and incorporated methodological guidance from the Joanna Briggs Institute, which informed the development of our pre‐registered protocol, the iterative refinement of inclusion criteria, and our approach to data extraction and synthesis [12, 13]. For reporting, we used the Preferred Reporting Items for Systematic Reviews and Meta‐analyses Extension for Scoping Reviews (PRISMA‐ScR) checklist [14]. The protocol was pre‐registered on Open Science Framework (https://doi.org/10.17605/OSF.IO/43EHP). We incorporated structured engagement of a multidisciplinary team throughout multiple stages of the review, including haematology, emergency medicine, and HTC staff. Team members contributed to protocol development by shaping the research question, scope, and definitions of key concepts, and assisted with interpretation of findings by validating clinical relevance and identifying gaps in current practice. Reflexivity was addressed by recognizing that our teams’ backgrounds could influence framing of the research question and interpretation of evidence; to mitigate potential bias, we engaged the team throughout protocol development, including creating and testing the screening tool, and conducted independent screening, data extraction, and analysis in duplicate. Ongoing team discussions and integration of diverse perspectives further enhanced transparency and rigor. Eligibility Criteria Eligibility criteria are outlined in Table 1. Studies were eligible for inclusion if they examined barriers to guideline‐concordant ED care and/or evaluated interventions aimed at improving ED care for people with bleeding disorders. Relevant English‐language publications were assessed for inclusion without date limits applied. Studies were excluded if they focused on non‐ED care settings or included populations experiencing bleeding due to conditions unrelated to bleeding disorders. TABLE 1Eligibility criteria for scoping review structured in PICO format (population, intervention, comparator, outcomes).Inclusion criteriaExclusion criteria Population Both barrier‐ and intervention‐focused studies: People of any age, sex, race/ethnicity, comorbidity status, or geographic locationDiagnosed with a congenital or acquired bleeding disorder, including but not limited to: Haemophilia A or B (any inhibitor status)Von Willebrand DiseaseRare clotting factor deficiencies (Factor I, II, V, VII, X, XI, or XIII deficiency)Platelet function disorders (i.e., Glanzmann thrombasthenia, Bernard–Soulier syndrome)Bleeding disorder of unknown cause Healthcare providers involved in ED care for this population People with bleeding caused exclusively by conditions unrelated to bleeding disorders, including but not limited to: Liver diseaseDisseminated intravascular coagulationAntiplatelet or anticoagulant useHereditary haemorrhagic telangiectasia or other vascular malformations Preclinical studies Interventions Barrier‐focused studies: Any identified barrier to effective ED care, including but not limited to: System‐level barriers: lack of standardized protocols, poor triage prioritization, absence of pre‐defined order setsProcess‐related barriers: delays in ordering/administration of haemostatic therapy, inefficient workflowsEducational barriers: lack of provider knowledge or training, unfamiliarity with bleeding disorder managementCommunication barriers: inadequate coordination between ED and haematology teams, poor patient‐provider communicationResource barriers: limited access to clotting factor concentrates, inadequate staffing, absence of electronic health record decision support tools Intervention‐focused studies: Any intervention designed to improve ED care for people with bleeding disorders, including but not limited to: Educational: seminars, workshops, pamphlets, simulations, learning modulesElectronic medical record enhancements: alerts, order sets, care pathwaysSystem level: institutional ED protocols, workflow redesignsDigital: websites, mobile appsQuality improvement initiatives: plan‐do‐study‐act cycles, auditsCommunication: initiatives enhancing communication between ED staff and haematologists/HTCs Interventions implemented outside of the ED settingInterventions not designed for the bleeding disorders population Comparison · Pre‐intervention data within the same setting, if reported. Studies without comparators will still be included.N/A Outcomes Timeliness: time to triage, factor order, or factor administrationAccess: percentage receiving appropriate haemostatic therapy (type and dose), access to therapy at institutionClinical outcomes: morbidity, mortalityPatient or physician reported outcomes: satisfaction with careSystem‐level outcomes: triage priority, guideline availability, hospitalization rates N/A Types of evidence sources Observational studies, interventional studiesCase reports, editorialsConference abstracts published within the last five years, with attempts to identify publications derived from the abstractsEnglish language, with no restriction on publication year (apart from abstracts) Non‐English publications Abbreviations: ED, emergency department; HTC, haemophilia treatment centre.John Wiley & Sons, Ltd. Eligibility criteria for scoping review structured in PICO format (population, intervention, comparator, outcomes). Both barrier‐ and intervention‐focused studies: People of any age, sex, race/ethnicity, comorbidity status, or geographic location People of any age, sex, race/ethnicity, comorbidity status, or geographic location Diagnosed with a congenital or acquired bleeding disorder, including but not limited to: Haemophilia A or B (any inhibitor status)Von Willebrand DiseaseRare clotting factor deficiencies (Factor I, II, V, VII, X, XI, or XIII deficiency)Platelet function disorders (i.e., Glanzmann thrombasthenia, Bernard–Soulier syndrome)Bleeding disorder of unknown cause Diagnosed with a congenital or acquired bleeding disorder, including but not limited to: Haemophilia A or B (any inhibitor status)Von Willebrand DiseaseRare clotting factor deficiencies (Factor I, II, V, VII, X, XI, or XIII deficiency)Platelet function disorders (i.e., Glanzmann thrombasthenia, Bernard–Soulier syndrome)Bleeding disorder of unknown cause Haemophilia A or B (any inhibitor status) Haemophilia A or B (any inhibitor status) Von Willebrand Disease Von Willebrand Disease Rare clotting factor deficiencies (Factor I, II, V, VII, X, XI, or XIII deficiency) Rare clotting factor deficiencies (Factor I, II, V, VII, X, XI, or XIII deficiency) Platelet function disorders (i.e., Glanzmann thrombasthenia, Bernard–Soulier syndrome) Platelet function disorders (i.e., Glanzmann thrombasthenia, Bernard–Soulier syndrome) Bleeding disorder of unknown cause Bleeding disorder of unknown cause Healthcare providers involved in ED care for this population Healthcare providers involved in ED care for this population People with bleeding caused exclusively by conditions unrelated to bleeding disorders, including but not limited to: Liver diseaseDisseminated intravascular coagulationAntiplatelet or anticoagulant useHereditary haemorrhagic telangiectasia or other vascular malformations People with bleeding caused exclusively by conditions unrelated to bleeding disorders, including but not limited to: Liver diseaseDisseminated intravascular coagulationAntiplatelet or anticoagulant useHereditary haemorrhagic telangiectasia or other vascular malformations Liver disease Liver disease Disseminated intravascular coagulation Disseminated intravascular coagulation Antiplatelet or anticoagulant use Antiplatelet or anticoagulant use Hereditary haemorrhagic telangiectasia or other vascular malformations Hereditary haemorrhagic telangiectasia or other vascular malformations Preclinical studies Preclinical studies Barrier‐focused studies: Any identified barrier to effective ED care, including but not limited to: System‐level barriers: lack of standardized protocols, poor triage prioritization, absence of pre‐defined order sets System‐level barriers: lack of standardized protocols, poor triage prioritization, absence of pre‐defined order sets Process‐related barriers: delays in ordering/administration of haemostatic therapy, inefficient workflows Process‐related barriers: delays in ordering/administration of haemostatic therapy, inefficient workflows Educational barriers: lack of provider knowledge or training, unfamiliarity with bleeding disorder management Educational barriers: lack of provider knowledge or training, unfamiliarity with bleeding disorder management Communication barriers: inadequate coordination between ED and haematology teams, poor patient‐provider communication Communication barriers: inadequate coordination between ED and haematology teams, poor patient‐provider communication Resource barriers: limited access to clotting factor concentrates, inadequate staffing, absence of electronic health record decision support tools Resource barriers: limited access to clotting factor concentrates, inadequate staffing, absence of electronic health record decision support tools Intervention‐focused studies: Any intervention designed to improve ED care for people with bleeding disorders, including but not limited to: Educational: seminars, workshops, pamphlets, simulations, learning modules Educational: seminars, workshops, pamphlets, simulations, learning modules Electronic medical record enhancements: alerts, order sets, care pathways Electronic medical record enhancements: alerts, order sets, care pathways System level: institutional ED protocols, workflow redesigns System level: institutional ED protocols, workflow redesigns Digital: websites, mobile apps Digital: websites, mobile apps Quality improvement initiatives: plan‐do‐study‐act cycles, audits Quality improvement initiatives: plan‐do‐study‐act cycles, audits Communication: initiatives enhancing communication between ED staff and haematologists/HTCs Communication: initiatives enhancing communication between ED staff and haematologists/HTCs Interventions implemented outside of the ED setting Interventions implemented outside of the ED setting Interventions not designed for the bleeding disorders population Interventions not designed for the bleeding disorders population Timeliness: time to triage, factor order, or factor administration Timeliness: time to triage, factor order, or factor administration Access: percentage receiving appropriate haemostatic therapy (type and dose), access to therapy at institution Access: percentage receiving appropriate haemostatic therapy (type and dose), access to therapy at institution Clinical outcomes: morbidity, mortality Clinical outcomes: morbidity, mortality Patient or physician reported outcomes: satisfaction with care Patient or physician reported outcomes: satisfaction with care System‐level outcomes: triage priority, guideline availability, hospitalization rates System‐level outcomes: triage priority, guideline availability, hospitalization rates Observational studies, interventional studies Observational studies, interventional studies Case reports, editorials Case reports, editorials Conference abstracts published within the last five years, with attempts to identify publications derived from the abstracts Conference abstracts published within the last five years, with attempts to identify publications derived from the abstracts English language, with no restriction on publication year (apart from abstracts) English language, with no restriction on publication year (apart from abstracts) Non‐English publications Non‐English publications Abbreviations: ED, emergency department; HTC, haemophilia treatment centre. Search Strategy and Study Selection A comprehensive literature search of the MEDLINE, Embase, Scopus, Web of Science, and Cochrane Library databases was conducted from inception through 21 March 2025. The search strategy was developed in consultation with a medical librarian (DLL; Appendix 1). Retrieved records were uploaded into Covidence [Veritas Health Innovation, Melbourne, Australia] and duplicates were removed. Prior to formal screening, reviewers conducted a pilot screening exercise on a subset of records to calibrate understanding of eligibility criteria and ensure inter‐reviewer consistency. All titles and abstracts were then independently screened by two reviewers (L.G. and K.U.) using predefined eligibility criteria. Studies identified as potentially relevant were advanced to full‐text screening. Full text screening was performed in duplicate by two independent reviewers (L.G. and K.U.) to determine final eligibility. Disagreements at any stage were resolved through discussions between reviewers, with a third reviewer available for adjudication if consensus could not be reached. Articles available only as conference abstracts were searched for corresponding full‐text publications and included in the review if located. Data Extraction Data were independently extracted in duplicate by two reviewers (L.G. and K.U.) using a standardized data extraction tool developed and uploaded onto Covidence. Extracted data captured study design, study population, barriers, interventions (if applicable), outcomes, quality indicators, and study limitations. Discrepancies were resolved through discussion between reviewers and consensus. Synthesis of Results Data from included studies were summarized using descriptive statistics to provide a quantitative overview of the evidence. Due to heterogeneity in study populations, outcome definitions, and measurement approaches, pooled quantitative synthesis was not performed. Instead, outcomes were described narratively and presented as ranges across studies. Where studies reported summary measures (e.g., time to haemostatic therapy), these were reported descriptively without aggregation or transformation, and studies reporting medians were retained as presented. Narrative synthesis was conducted to synthesize qualitative findings. Studies were stratified according to whether they focused on identifying barriers or evaluating interventions. Within each category, key themes were identified and synthesized narratively. Results are presented using narrative, tabular, and graphical formats to illustrate the current evidence, most frequently identified barriers, most effective interventions, and overall outcomes. Results Study Characteristics A total of 3541 records were identified across the five databases after duplicate removal. Following title and abstract screening, 54 underwent full‐text review, and 17 met criteria for inclusion in this study (Figure 1). Of these, 11 were published articles [6, 7, 8, 9, 10, 11, 15, 16, 17, 18, 19] and six were conference abstracts [20, 21, 22, 23, 24, 25]. Most were published in or after 2020 (n = 10) [9, 10, 17, 18, 19, 21, 22, 23, 24, 25] and were single‐institutional studies (n = 10) [6, 8, 15, 18, 19, 20, 21, 22, 23, 25]. PRISMA flow diagram illustrating the number of records identified, screened, and included in the scoping review, as well as reasons for exclusion. Studies were excluded after full‐text review if reported bleeding events were unrelated to bleeding disorders, not conducted in the ED setting, were not published in English, focused exclusively on general guidelines, or did not report outcomes related to patient care or stakeholder perspectives. Eight studies were conducted in the United States [8, 10, 11, 15, 16, 17, 18, 19], with the remaining studies from Canada (n = 3) [21, 22, 24], Italy (n = 3) [7, 9, 23], the United Kingdom (n = 2) [6, 25], France (n = 1) [20], and Germany (n = 1; combined US and German cohort) [10]. The majority were performed exclusively in urban settings (n = 14) [6, 7, 8, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25], with three presumed to involve a mix of urban and rural settings based on study design [9, 10, 11]. Patients were explicitly under the care of an HTC in 12 of 17 studies [6, 7, 8, 9, 15, 17, 18, 20, 21, 22, 24, 25], whereas the remainder were unclear. The evidence base was weighted strongly toward haemophilia, with 10 studies on haemophilia alone [8, 9, 10, 11, 16, 17, 19, 20, 22, 23], one on vWD alone [15], and six on multiple types of bleeding disorders (all of which also included haemophilia) [6, 7, 18, 19, 24, 25]. Although acquired bleeding disorders were included in the eligibility criteria, they were underrepresented in the included studies, with only one study focused specifically on acquired haemophilia [11]. Four studies were performed in exclusively paediatric populations [8, 17, 18, 23], two in both adult and paediatric [9, 20], seven in exclusively adult populations [6, 15, 16, 19, 21, 22, 25], and some were unspecified as focused on HCPs [7, 10, 11, 24]. Terminology describing treatment varied across included studies, with terms such as “hemostatic therapy,” “factor replacement,” and “treatment” used inconsistently and, in some cases, interchangeably. For this review, these terms were synthesized under the broader concept of haemostatic therapy, defined as administration of factor concentrates, bypassing agents, or desmopressin. Where relevant, distinctions between specific therapies were preserved in the reporting of individual study outcomes. Study Focus and Designs Ten studies focused on identifying barriers to guideline‐concordant ED care [6, 8, 9, 10, 11, 15, 16, 20, 21, 22], while seven evaluated interventions aimed at improving ED management [7, 17, 18, 19, 23, 24, 25]. Barrier‐Focused Studies Barrier‐focused studies used retrospective chart reviews (n = 5) [8, 15, 16, 21, 22], descriptive surveys (n = 3) [10, 11, 20], clinical audits [6], or interviews [9]. Patients were identified for chart reviews by assessing ED visits within institutional databases of patients under HTC care or by extracting ED visits with ICD codes consistent with bleeding disorder‐related presentations. The mean duration of data collection was 3.4 years (range: 1–6 years). The primary objectives of the barrier‐focused studies were to assess adherence to clinical national guidelines [6, 21], evaluate time to administration of haemostatic therapy [6, 8, 10, 21, 22], identify gaps in care [10], examine use of individualized care plans [22], characterize presenting complaints for people with bleeding disorders [15, 16], explore factors contributing to prolonged ED stays [20], and assess healthcare professional education needs [9, 11]. The types of bleeding disorders assessed varied, with some studies investigating multiple types; the most frequently studied condition was haemophilia A or B (n = 9) [6, 8, 9, 10, 11, 16, 20, 21, 22], followed by von Willebrand disease (n = 3) [6, 15, 21], rare factor deficiency (n = 1) [6], and platelet function defect (n = 1) [6]. Most studies reported multiple barriers per study (Table 2). These included communication and coordination challenges between ED and haematology or HTCs (n = 7) [6, 9, 10, 15, 16, 20, 22], limited knowledge of guidelines or management (n = 4) [6, 9, 10, 11], lack of institutional ED guidelines or standardized care pathways (n = 4) [6, 8, 9, 10], limited access to haemostatic therapies (n = 3) [9, 10, 16], and electronic medical record (EMR) limitations (n = 1) [6]. Reported impacts of these barriers included missed or delayed haemostatic therapy administration (n = 7) [6, 8, 10, 15, 16, 21, 22], mortality due to intracerebral haemorrhage following delayed treatment (n = 1) [6], and prolonged ED length of stay (n = 1) [20]. TABLE 2Summary of barrier‐focused studies including population characteristics, identified barriers, and reported outcomes. Author (Year) Population N‐ value Time‐frame Barrier Outcomes Type Details deMoer‐loose (2020), full articleHealthcare providers who manage haemophilia with inhibitors 218 in USA, 98 in Germany 2017EducationGerman HCPs ranked improved education/knowledge as the second most important factor for enhancing care outcomes.Only 21% of US and 18% of German HCPs provided bypassing agent in <60 min.Lack of institutional guidelines15% of US and German HCPs had access to ED guidelines. A proportion (27% US and 8% German) were unsure whether they had institutional guidelines.Resource limitationsFor bypassing agents, 44% of US and 38% of German HCPs reported no access in their institutions. Those with access reported significant restrictions to use (57% to NovoSeven, 51% to FEIBA in the US), with need to re‐diagnose or receive approval to use. U.S. and German HCPs ranked availability of bypassing agents as the first and third most important factor, respectively, in improving outcomes.Communi‐cation with haematology28% of US patients and 47% of German patients were referred to an HTC after discharge; 43% of US and 20% of German patients were referred to another specialist (most often a haematologist). U.S. HCPs ranked haematology consult as the second most important factor in improving outcomes.Fowler (2012), full articleAdult patients with haemophilia, vWD, platelet function defects, and rare factor deficiencies75 ED visits from 45 patients2007‐2010EducationED staff received limited training on managing bleeding disorders; although HTC nurses provided some training sessions, there was limited consistency due to high ED staff turnover rate.Increased time to haemostatic therapy, with an average of 86 min. One patient was inappropriately triaged and died from an intraventricular bleed.EMR limitationsMedical records were not accessible out of hours.Lack of institutional guidelineNo institutional ED protocol available.Communi‐cation with haematology47% of HTCs were contacted by ED to arrange adequate follow‐up, and only 27% received haematology consultation (both of which are specified in UK guidelines).Hoang (2018), conference abstractAdult and paediatric patients with haemophilia126 ED visits from 43 adult patients, 295 ED visits from 34 paediatric patients2010‐2016Communi‐cation with haematologySlight improvement in wait times when sent in by a haematologist (1.8 h vs. 2.5 h, p = 0.03).Prolonged wait times of 1.8 h for paediatric and 3.9 h for adult patients.Kraft (2024), conference abstractAdult patients with haemophilia or vWD241 ED visits from 122 patients2019‐2022N/AStudy reported adherence to standards for ED care and noted outcomes; did not specify barriers.50% of ED visits for bleeding events received haemostatic therapy. Median CTAS score was 2. Median time from triage to haemostatic therapy administration was 2.9 h for factor and 3.4 h for desmopressin. Severe bleeding disorders were associated with longer delays (mean 5.0 h vs. 2.8 h, p < 0.05).Livesey (2024), full articleAdult patients with vWD385 ED visits from 183 patients2004‐2009Communi‐cation with haematology More patients received treatment when referred to ED by haematology (83% vs. 25%), and only patients who were not referred by haematology were discharged with NSAIDS/ASA (5% overall). 100% of patients who received haemostatic treatment received an inpatient heme consult, but only 16% were subsequently referred to a haematologist after ED discharge. 17.4% received haemostatic therapy (24.7% of patients with known bleed, 21.3% of patients with suspected bleeds, and 11.0% of patients with non‐bleed presentation).Nuss (2002), full textAdult patients with haemophilia (male only)125 ED visits from 51 patients1998Communi‐cation with haematologyOf the 12 patients who did not receive factor, only two were discussed with haematology. Only one of five patients who experienced factor administration error received a haematology consult.84.4% (n = 65/77) of patients received factor for indicated visits, with a factor administration error rate of 7.7% (n = 5; wrong concentrate or dose). Delays noted with 100% of non‐indicated tests (n = 10/10).Resource limitationsTwo patients were transferred to another hospital due to lack of factor availability.Pollio (2022), full textHealthcare providers who manage haemophilia A in both adult and paediatric patients21 ED physicians2019Lack of institutional guidelinesInstitutional guidelines available in 56.5% of EDs, of which only 38.5% were formalized and mandatory. 52% of EDs did not classify haemophilia as urgent unless presented with actual/suspected bleeding event, 39% treated always as urgent, and 9% were unspecified.As the format of the study was interviews, patient‐specific outcomes were not quantified.Communi‐cation with haematologyHTC contacted for 67% of adult patients and 57% of paediatric patients with known haemophilia after discharge from ED.Resource limitations43% of EDs needed to request for another hospital to send factor. 7% ended up using an alternate treatment.Education52% of ED physicians reported never having received specific training on managing bleeding disorders, with 48% self‐rating knowledge as basic and 0% rating as excellent. 86% were interested in receiving knowledge on management, with preference for dedicated sessions during conferences, small workshops, or online learning.Reding (2012), full articleHealthcare providers who manage acquired haemophilia302 physicians (approx. 50 per specialty)2010EducationAlthough 85% of ED physicians reported having managed the first presentation of a bleeding disorder in the past, only 20% had managed acquired haemophilia before.As the format of this study was an online survey, patient‐specific outcomes were not quantified.Sharieff (2001), full articlePaediatric patients with bleeding disorders23 ED visits from 11 patients1996‐1998Lack of institutional guidelinesAuthors developed a protocol to allow triage to place orders for haemostatic therapy while awaiting ED physician assessment.Average time from triage to factor was 1.7 h. No morbidity/mortality complications were observed with the delay.Uminski (2023), conference abstractAdult patients with haemophilia393 ED visits from 191 patients2015‐2021Communi‐cation with haematologyLess than 20% of ED visits were associated with a haematology consult.Median time to factor was 4.2 h. CTAS score was usually 2–3. 20% of patients received haemostatic therapy. 40% of patients underwent bloodwork testing. Over time, ED physicians accessed bleeding disorders individualized care plans more often (from 27% to 91%).Abbreviations: CTAS, Canadian triage and acuity score; ED, emergency department; EMR, electronic medical record; HCP, healthcare provider; vWD, von Willebrand disease.John Wiley & Sons, Ltd. Summary of barrier‐focused studies including population characteristics, identified barriers, and reported outcomes. 218 in USA, 98 in Germany More patients received treatment when referred to ED by haematology (83% vs. 25%), and only patients who were not referred by haematology were discharged with NSAIDS/ASA (5% overall). 100% of patients who received haemostatic treatment received an inpatient heme consult, but only 16% were subsequently referred to a haematologist after ED discharge. Abbreviations: CTAS, Canadian triage and acuity score; ED, emergency department; EMR, electronic medical record; HCP, healthcare provider; vWD, von Willebrand disease. Intervention‐Focused Studies Interventional studies most commonly evaluated patient outcomes (n = 5; e.g., time to haemostatic therapy, factor dosing) [17, 18, 19, 23, 24], while two targeted HCP practices (e.g., websites, EMR enhancements, and new ED pathways) [7, 25]. Study designs included quality improvement (QI) approaches (n = 3) [17, 18, 24] and one each of retrospective chart review [23], clinical audit [25], prospective cohort [7], and quasi‐experimental studies [19]. Data collection spanned a mean duration of 4.2 years across pre‐ and post‐intervention phases (range: 1–8 years). Haemophilia remained the most studied bleeding disorder (n = 4) [17, 18, 19, 23], with two including all bleeding disorders [7, 24], and one each of von Willebrand disease [18], rare factor deficiency [18], and unspecified type of bleeding disorder [25]. Intervention‐focused studies implemented a range of strategies aimed at improving ED care, most commonly through multimodal QI initiatives (Table 3). These included EMR enhancements (n = 6), such as creation of order sets with recommended haemostatic therapies and haematology consult prompts [17, 19], triage flags notifying ED HCPs about known diagnoses of bleeding disorders [18], and more prominently displayed individualized care plans [7, 17, 18, 24, 25]. Educational interventions (n = 3) targeted ED HCPs through training on guideline‐based ED management [17, 18, 19], and patients and caregivers through sessions on self‐advocacy and preparing for ED visits [18]. ED‐specific care pathways (n = 4) were developed to standardize triage and workflow. Communication and collaboration‐focused initiatives (n = 2) aimed to strengthen collaboration between ED teams and haematology, including use of wallet cards and pre‐arrival communication protocols [17, 18]. One study developed a web‐based platform containing clinical guidelines and management algorithms to support real‐time decision making [7]. Key characteristics of interventions, including care settings, intervention components, implementation processes, and outcome definitions, are summarized in Table 4. TABLE 3Summary of intervention‐focused studies including population characteristics, interventions, and reported outcomes.Author (Year)Population N‐ valueTime‐frameInterventionOutcomesTypeDetailsBertoni (2023), conference abstractPaediatric patients with haemophilia A177 ED visits from 32 patients2015‐2019 (pre‐inter‐vention), 2020–2023 (post‐inter‐vention)New pathway/ algorithmImplemented ED algorithm but did not specify details of algorithm.Decreased triaging as lower priority by 15%, decreased time to factor (84 min to 59 min), decreased diagnostic testing order prior to factor by 39% (42% to 3%), decreased hospitalizations (no statistics reported).Hodgson (2024), conference abstractHealthcare providers and adult patients with any bleeding disordersNot reportedNot reportedEMR enhance‐mentTransitioned paper wallet cards to EMR care plans, which were searchable and triggered pushed alerts. Communication plan created to inform ED staff and patients of the new digital care plan.Increased patient and provider satisfaction (no quantitative data reported).Kendel (2024), full articleHealthcare providers (haematology, ED) who manage haemophilia A and B in paediatric patients. Monitored outcomes in patient metrics.219 ED visits by 209 patients2015‐2016 (pre‐inter‐vention); 2017–2022 peri/post inter‐ventionEducation Training simulations for ED providers regarding management of common presentations in haemophilia. Annual education sessions for haematologists regarding updating EMR problem list. Lectures for haematology trainees with pre‐ and post‐tests regarding different factor products and dosing recommendations. Increased factor dosages in optimal range (71% to 82%). Incorrect dosages were usually underdosed (74%) and were not associated with complications or additional medical interventions. Although only 18% of ED visits used the designed haemophilia order set, 97% of those who did used the correct factor dose.EMR enhance‐ment Developed standardized problem list with information regarding each patient's haemophilia type, severity, factor product with goal dosing for major vs. minor bleeds. Added examples of major vs. minor bleeds at recommendation of ED MDs. Order set linked to institutional guidelines and product orders with recommended dosages that auto‐populate onto patient charts. Commun‐ication Haematology team to call ED HCPs and pharmacist when patient is being sent to ED. Pharmacy instructed to review EMR problem list after receiving factor orders. Littner (2025), full articleHealthcare providers (ED) and paediatric patients with haemophilia A or B, von Willebrand disease, or rare factor deficiency504 ED visits from 133 patients2019‐2024Education Patients were provided written instructions on calling HTC or haematology MD on call prior to presenting to ED, and educated on presenting wallet cards. Written instructions were available in English, Spanish, and Arabic. Patients and caregivers attended two in‐person educational programs about preparing for ED visit and advocacy skills. ED HCPs attended in‐person education session regarding guidelines and factor administration. Posters were hung in ED HCPs bathrooms and breakrooms and were changed monthly. ED HCPs also given snacks with packaging that had notes on management. Collaborated with a popular ED blog/podcast to develop articles on ED care for haemophilia and evaluating/treating patients on emicizumab. Decreased time to factor administration with multiple iterative rounds of interventions, from 1.83 h to 0.78 h.Commun‐icationWallet cards for patients (included factor dose, definition of bleeds, treatment protocol, individualized information, ± emicizumab, and record that patients were allowed to administer factor brought from home) updated at each clinic visit.EMR enhance‐ment Updated problem lists on EMR to include information on each patient's bleeding disorder treatment. FYI flags added to EMR with alert regarding high bleeding risk and guidelines (Factor First, venous/port access details, and to contact haematology prior to any procedures). Flag fatigue was noted by ED HCPs. Factor package insert linked in EMR to allow nurses to find patient's treatment instructions. Ndai (2024), full article Adult patients with haemophilia A and B 43 ED visits by 29 patients 2020‐2023 EducationAll ED HCPs received training by haematologists through didactic lectures, case‐based discussions, and hands‐on exercises/simulation sessions.Decreased time to factor administration (5.63–3.15 h), time to factor order (3.77–2.05 h), and time from factor order to administration (1.87 h to 1.1 h). Increased haematology consults (31.8% to 47.6%).EMR enhance‐ment/ Communi‐cationDeveloped factor replacement order sets for initial/emergent treatment and continuous treatment, such that no other methods for ordering factor were possible. Order set also included reminder that treatment was prioritized over diagnostic tests as well as haematology referral.Patel (2020), conference abstractAdult patients with bleeding disorders (unspecified type)61 ED visits from 39 patients2018‐2019New pathway/ algorithmAfter 2015 audit showed variable out‐of‐hours care, authors developed new pathway directing patients to seek out‐of‐hours care from ED rather than the haematology ward.No reported pre‐intervention outcomes so unable to assess for change. Reported post‐intervention time to factor of 2.17 h, time to assessment of 0.67 h, haemostatic therapy treatment rate of 92%, hospitalization rate of 26%, haematology consults in 77%.EMR enhance‐mentsIntroduced individualized care plans on EMR.Tagliaferri (2016), full articleHealthcare providers who manage any bleeding disorderNot report‐ed2012‐2013EMR enhance‐ment HTC staff uploaded patient information onto a database. Patients had access and entered information on home bleeds and treatments. Database was accessible on the internet and linked to EMR. Website used 14,000 times over 2 years, of which 1700 were by ED. Algorithm used to make treatment decisions for 206 patients. Additional statistics were reported for two reference ED sites; authors did not report pre‐intervention values. Noted increased HTC involvement, decreased time to treatment by approx. 40 min, increased availability of on call haematologist, and increased prioritization during triage. Website Developed website tailored for ED physicians. Provides information on ED treatment plan, algorithms, and drug dosages. Main home page of website discusses the factor first principle. Patients were also able to use the website for guidance on home management of minor bleeds. New pathway/ algorithmNew care pathway produced in consultation with expert advice. Described diagnostic criteria for bleeding disorders, triaging, treatment urgency, and treatment recommendations (haemostatic therapy, preoperative advice, and drugs to avoid).Abbreviations: ED, emergency department; EMR, electronic medical record; FYI, for your information; HCPs, healthcare professionals; HTC, haemophilia treatment centre.John Wiley & Sons, Ltd. Summary of intervention‐focused studies including population characteristics, interventions, and reported outcomes. Training simulations for ED providers regarding management of common presentations in haemophilia. Annual education sessions for haematologists regarding updating EMR problem list. Lectures for haematology trainees with pre‐ and post‐tests regarding different factor products and dosing recommendations. Developed standardized problem list with information regarding each patient's haemophilia type, severity, factor product with goal dosing for major vs. minor bleeds. Added examples of major vs. minor bleeds at recommendation of ED MDs. Order set linked to institutional guidelines and product orders with recommended dosages that auto‐populate onto patient charts. Haematology team to call ED HCPs and pharmacist when patient is being sent to ED. Pharmacy instructed to review EMR problem list after receiving factor orders. Patients were provided written instructions on calling HTC or haematology MD on call prior to presenting to ED, and educated on presenting wallet cards. Written instructions were available in English, Spanish, and Arabic. Patients and caregivers attended two in‐person educational programs about preparing for ED visit and advocacy skills. ED HCPs attended in‐person education session regarding guidelines and factor administration. Posters were hung in ED HCPs bathrooms and breakrooms and were changed monthly. ED HCPs also given snacks with packaging that had notes on management. Collaborated with a popular ED blog/podcast to develop articles on ED care for haemophilia and evaluating/treating patients on emicizumab. Updated problem lists on EMR to include information on each patient's bleeding disorder treatment. FYI flags added to EMR with alert regarding high bleeding risk and guidelines (Factor First, venous/port access details, and to contact haematology prior to any procedures). Flag fatigue was noted by ED HCPs. Factor package insert linked in EMR to allow nurses to find patient's treatment instructions. Ndai (2024), full article Adult patients with haemophilia A and B 43 ED visits by 29 patients 2020‐2023 HTC staff uploaded patient information onto a database. Patients had access and entered information on home bleeds and treatments. Database was accessible on the internet and linked to EMR. Website used 14,000 times over 2 years, of which 1700 were by ED. Algorithm used to make treatment decisions for 206 patients. Additional statistics were reported for two reference ED sites; authors did not report pre‐intervention values. Noted increased HTC involvement, decreased time to treatment by approx. 40 min, increased availability of on call haematologist, and increased prioritization during triage. Developed website tailored for ED physicians. Provides information on ED treatment plan, algorithms, and drug dosages. Main home page of website discusses the factor first principle. Patients were also able to use the website for guidance on home management of minor bleeds. Abbreviations: ED, emergency department; EMR, electronic medical record; FYI, for your information; HCPs, healthcare professionals; HTC, haemophilia treatment centre. TABLE 4Setting, components, implementation process, and outcome definitions for intervention‐focused studies.InterventionOutcomesAuthor (Year), TypeSettingPopulationComponentsImplementation MethodMeasuredDefinitionBertoni (2023), conference abstractSingle‐centre, ItalyPaediatric, haemophilia AED algorithmNot specifiedPre‐post algorithm; time to haemostatic therapy, morbidity (i.e., bleeding complications), percentage triaged as lower acuity, number of hospitalizations, percentage of ED encounters where factor replacement givenTime to haemostatic therapy = time from physician assessment to infusion; triaged as lower priority if classified as a “green code”Hodgson (2024), conference abstractMulti‐centre, CanadaAge unspecified, all bleeding disordersDigital ED exceptional care plan linked to EMREducation and communication plan was developed to increase ED staff and patient awareness of the initiative.Patient and provider satisfactionPatient satisfaction = feelings of reassurance regarding improved communication; physician satisfaction = increased confidence in managing careKendel (2024), full textMulti‐centre, USAPaediatric, haemophilia A and B without inhibitorsTraining simulations, EMR problem list, orderset linked to institutional guidelines and order recommend‐ationsAnnual training for haematology physicians regarding updating the EMR problem list. Not specified but information regarding EMR enhancements may have been relayed during training simulationsOptimal factor dosing range, rate of orderset useOptimal dose = 90%–120% of calculated goal dose based on patient's weight at time of ED visitLittner (2025), full articleSingle‐centre, USAPaediatric (but follow‐up to 25 years of age), all bleeding disordersPatient education sessions, ED education sessions, posters in ED, snacks with packaging notes, collaboration with ED blogs and podcasts, wallet cards for patients, EMR flagsPatients received education sessions and written instructions on calling HTC or haematology prior to ED visits; ED HCPs received education sessions regarding guidelinesTime to haemostatic therapyTime to haemostatic therapy = time from ED arrival to therapy infusionNdai (2024), full articleSingle‐centre, USAAdult and paediatric, haemophilia A and B (inhibitor status unspecified)ED HCP education sessions and simulations, EMR ordersets As part of QI initiative, all ED HCPs at the institution were enrolled Time to haemostatic therapyTime to haemostatic therapy = time between ED arrival to factor order, factor order to factor administration, and ED arrival to factor administrationPatel (2020), conference abstractSingle‐centre, UKPaediatric, haemophilia A and B (inhibitor status unspecified)ED algorithm, EMR exceptional care plansNot specifiedTime to haemostatic therapy, overall haemostatic therapy treatment rate, hospitalization rate, number of ED visits which resulted in a haematology consultTime to haemostatic therapy definition was not specifiedTagliaferri (2016), full articleMulti‐centre, ItalyAge unspecified, all bleeding disordersEMR exceptional care plan (linked through a patient information database), website for ED HCPs with guidelines and algorithmsExtensive education and training program of all ED HCPs, local health authorities, and hospitals to teach how to use the website and databaseNumber of website accesses, HTC involvement, time to haemostatic therapy, availability of on call haematologist, triaging priorityTime to haemostatic therapy = ED triage to factor administrationAbbreviations: ED, emergency department; HCP, healthcare professional; QI, quality improvement.John Wiley & Sons, Ltd. Setting, components, implementation process, and outcome definitions for intervention‐focused studies. As part of QI initiative, all ED HCPs at the institution were enrolled Abbreviations: ED, emergency department; HCP, healthcare professional; QI, quality improvement. Key Themes Seven inter‐related themes were identified (Figure 2): (1) delayed or missed haemostatic therapy; (2) education and awareness limitations among ED HCPs; (3) absence of standardized institutional protocols and care pathways; (4) EMR‐related limitations; (5) communication and collaboration challenges between haematology or HTCs and ED; (6) resource limitations; and (7) stakeholder perspectives. Key barriers and corresponding interventions identified from the scoping review of emergency department care for people with bleeding disorders. Domains reflect areas for targeted quality improvement. Created in BioRender. Uminski, K. (2025) https://BioRender.com/r7ehije. ED, emergency department; HTC, haemophilia treatment centre; EMR, electronic medical record. Delayed or Missed Haemostatic Therapy Delays in administration of haemostatic therapy were quantified in eight single‐institution studies; reported times to therapy varied widely, with time to therapy ranging from 1.4 to 5.6 h [8, 18, 19, 20, 21, 22, 23, 25]. In one study, longer delays were noted among patients with more severe bleeding disorders (5.0 h vs. 2.8 h) and when DDAVP was used instead of factor concentrates (3.4 h vs. 2.9 h) [21]. Only 9%–17% of patients received haemostatic therapy within 60 min in one retrospective review [18]. The primary contributor to treatment delays was the time interval from ED triage to haemostatic therapy order, with the longest delays occurring from ED triage to rooming for haemophilia, and from initial physician assessment to therapy order for von Willebrand disease [19, 21]. Across four interventional studies using multimodal methods, the reduction in time to haemostatic therapy ranged from 0.4 to 2.5 h) [7, 18, 19, 23]. Rates of haemostatic therapy administration varied substantially across institutions; some centres reported that approximately 20% of patients received appropriate therapy despite confirmed bleeding events [15, 22], whereas others noted higher rates of 50% and 84% [16, 21]. Factor dosing errors were observed in two studies, with reported rates of 8% and 29% [16, 17]. Four studies identified prolonged ED stays related to diagnostic testing performed prior to haemostatic therapy administration [16, 20, 22, 23]. Patients were generally triaged as urgent or emergent (Canadian Triage Acuity Scale 2–3) [21, 22]. Data on clinical outcomes, such as morbidity and mortality, were limited due to the retrospective chart review design of most studies. One study documented a fatal case involving a patient with haemophilia B, who was incorrectly triaged and died from an intraventricular haemorrhage after 17 h without receiving factor therapy [6]. In contrast, a study from an institution with a shorter than average time to therapy of 1.7 h reported no adverse clinical outcomes [8]. Education and Awareness Given the specialized nature of bleeding disorders, many ED HCPs reported limited familiarity with management or with current clinical guidelines [6, 9, 10, 11, 17, 18, 19]. A study of ED physicians across 23 Italian hospitals noted that 52% had never received specific training in bleeding disorders care, with 48% rating their knowledge as basic and none as excellent [9]. Familiarity also varied by disorder type; while 85% reported having managed the initial presentation of a bleeding disorder, only 20% had encountered acquired haemophilia [11]. One study observed that although HTC nurses provided periodic training to ED HCPs, high turnover rates hindered continuity [6]. Despite these challenges, there was substantial interest in increasing education. In a survey of German ED HCPs ranked improved education as the second most important factor in enhancing care quality; likewise, 86% of Italian ED HCPs expressed interest in additional training when interviewed, with preferences for conferences, workshops, or online formats [9, 10]. Educational interventions were frequently implemented as part of multimodal approaches that also included EMR enhancements or improved communication strategies. Interventions for ED healthcare providers included training simulations, didactic sessions regarding guidelines and haemostatic therapy dosing, and case‐based discussions [17, 18, 19]. One study also incorporated education for people with bleeding disorders and caregivers focused on self‐advocacy, pre‐ED arrival communication with HTC or haematologist, and use of wallet cards [18]. Additional strategies included posters in ED, snack packaging containing key messages, and collaborations with ED blogs and podcasts [19]. Reported outcomes from interventions included 44% and 57% decreases in time to factor administration (from 5.63 to 3.15 h, and from 1.83 to 0.78 h, respectively), an 11% increase in appropriate factor dosing (from 71% to 82%), and a 16% increase in haematology consultations by ED (from 32% to 48%) [17, 18, 19]. Lack of Institutional Standardized Care Pathways The absence or inconsistent use of ED‐specific standardized care pathways was a common barrier across studies [6, 7, 8, 9, 10, 17, 23, 25]. In a survey of ED HCPs in the United States and Germany, only 15% reported access to ED‐specific protocols, while 27% of US and 8% of German respondents were unsure whether such protocols existed in their institutions [10]. Inconsistent protocol use was identified as a barrier to timely haemostatic therapy in another US study [17]. Similarly, a single‐centre study from the UK reported no existing ED protocols for bleeding disorders management [6]. In Italy, protocols were available in only 13 of 23 EDs surveyed, with only five being formalized and mandatory; moreover, substantial variability existed in triage prioritization among these protocols, with 52% classifying haemophilia as non‐urgent unless presenting with a bleeding event, 39% as always urgent, and 9% unspecified [9]. Four studies implemented ED‐specific care pathways, which included routine assignment of higher triage priority, triage‐initiated ordering of haemostatic therapy, and diagnostic and treatment algorithms [7, 8, 23, 25]. Details of algorithm content were minimally reported. Implementation of standardized pathways was associated with reported improvements in process metrics. Two studies reported decreased time to factor administration by 30% and 36% (84–59 min and 110–70 min, respectively), while another reported a post‐intervention time of 130 min without baseline data [7, 23, 25]. Additional outcomes included a 39% reduction in pre‐treatment diagnostic testing (from 42% to 3%), decreased hospitalization rates, and improved triage prioritization (no quantitative data provided for the latter two outcomes) [7, 23]. EMR Limitations Limitations in EMR systems were often associated with delayed recognition of people with bleeding disorders [6, 7, 17, 18, 19, 24, 25]. Patient records were inaccessible outside of regular working hours at one academic institution [6]. EMR enhancements were the most frequently implemented intervention and included development of digital individualized care plans or problem lists detailing the diagnosis, severity, and treatment regimen [7, 17, 18, 24, 25]; EMR‐integrated order sets containing recommended factor products and dosages, links to institutional guidelines, reminders of the “Factor First” principle, and prompts for haematology consultation [17, 19]; and triage flags alerting HCPs to the individualized care plan or high bleeding risk [18, 24]. These interventions were consistently implemented alongside education initiatives or new ED care pathways. Challenges with uptake included flag fatigue (where repeated EMR flag alerts desensitized HCPs and reduced engagement), while another study reported only 19% of ED visits used the recommended order set; however, 97% of order set users administered the correct factor dose [17, 19]. These interventions were associated with improved clinical and process outcomes, including reduced time to haemostatic therapy administration, increased haematology involvement, higher dosing accuracy, improved triage prioritization, and greater patient and HCP satisfaction [7, 17, 18, 19, 24, 25]; however, causal relationships cannot be established given the predominantly pre‐post observational study design. As these EMR enhancements were implemented alongside other strategies, detailed outcomes data are presented in earlier sections and summarized in Table 3. Communication and Collaboration With Haematology and HTCs Haematology and HTC involvement was associated with improved ED care, including shorter ED wait times (110 vs. 150 min), increased rates of appropriate therapy (83% vs. 25%), and lower use of contraindicated NSAIDs (0% vs. 5%) [15, 20]. Despite these benefits, consultation rates remained low and variable. European centres in Italy, the UK, and Germany reported moderate consultation rates between 40% and 70%, although one UK study noted rates as low as 27% [6, 9, 10, 25]. In contrast, Canadian and US studies reported rates closer to 20% [10, 22]. US HCPs ranked haematology involvement as the second most important factor in improving ED care and noted limited access to haematology in their institutions [10]. Even when clinical errors occurred, haematology consultation was infrequent; in one study, only two of 12 patients who did not receive indicated therapy and one of five with dosing errors received haematology consultation [16]. Three interventions aimed to enhance haematology involvement, including integrating haematology consult prompts into order sets, establishing pre‐arrival communication protocols between haematology and ED, and educating people with bleeding disorders to notify haematology prior to ED presentation [17, 18, 19]. Reported outcomes included 16% increase in consult rates (32%–48%), 11% improvement in appropriate factor dosing, and reduction in time to factor administration to below 60 min [17, 18, 19]. One study also observed increased on‐call haematologist availability, although did not provide quantitative data [7]. Resource Limitations Limited availability of factor products and bypassing agents were reported as persistent barriers to timely care. In one Italian study, 43% of EDs required factor delivery from another institution and 7% administered alternative therapies as a result, contributing to delayed or suboptimal treatment [9]. Another institution transferred two of 12 untreated patients to another hospital due to lack of factor on‐site [16]. In yet another study, approximately 40% of US and German HCPs reported lack of access to bypassing agents in their institutions [10]. US HCPs noted significant restrictions to use and ranked access to resources as the most important factor affecting outcomes, whereas German HCPs also described institutional barriers, including internal processing delays and requirements to re‐diagnose prior to treatment [10]. These resource limitations were not directly addressed in intervention studies and may require broader hospital‐ or system‐level strategies. Stakeholder Perspectives Stakeholder engagement was rarely solicited and limited to interventional studies. Only two studies included perspectives from people with bleeding disorders or caregivers, with one study reporting increased patient satisfaction with digitalized care plans over paper, and another targeting patient and caregiver education through sessions and written materials [18, 24]. Four studies sought HCP input through interviews, feedback, or recruitment into multidisciplinary QI teams [7, 10, 17, 24]. One study described HCP satisfaction with digitalized care plans, while another identified EMR flag fatigue as a barrier to uptake of EMR enhancements [17, 24]. Another study developed a new care pathway in consultation with advice from an expert physician group [7]. A survey of U.S. and German ED physicians demonstrated differing priorities for improving acquired haemophilia care; US HCPs emphasized access to resources, haematology involvement, and early recognition of disease, whereas German HCPs prioritized access to past medical records, improved education, and resource availability [10]. Overall, engagement of people with bleeding disorders, caregivers, and HCPs was infrequent, and details regarding specific stakeholder feedback provided or whether it informed intervention design was limited. Discussion Over the past decade, increasing attention has been directed towards the issue of non‐adherence to international guidelines and best practices for ED management of people with bleeding disorders. To address this persistent challenge, we identified key outcomes and themes related to barriers to ED management and effectiveness of interventions. Although existing studies have described site‐specific barriers and interventions, our findings demonstrate a consistent, multi‐institutional, and international trend of delayed time to haemostatic therapy and other barriers that may be associated with reduced quality of care. Barriers to optimal ED care are multifactorial. Limited educational experiences and infrequent clinical exposure were reported contributors to reduced HCP confidence in knowledge, despite strong interest in additional training [6, 10, 11, 17, 18, 19]. Inadequate access to medical records may limit timely identification of people with bleeding disorders [6]. Absence of institutional guidelines may be associated with variabilities in clinical practice, including inappropriate triage, variations in diagnostic approaches, and delayed or missed administration of haemostatic therapy [6, 7, 9, 10, 23, 25]. Haematology consultation is associated with improved time to haemostatic therapy but remains underused, even when recommended by institutional protocols [6, 7, 10, 15, 16, 19, 22, 25]. Communication with HTCs for post‐ED discharge follow‐up was inconsistent, which may represent missed opportunities for ensuring continuity of care [9, 10, 15]. In response to these barriers, most interventions combined EMR enhancements with HCP education to enhance management practices [7, 17, 18, 19, 24, 25]. EMR tools allow for integration of guideline‐concordant components, such as prompts to consult haematology, prepopulated treatment order sets, and triage flags, which support adherence to guidelines while minimizing cognitive burden on ED HCPs [26]. These findings suggest that EMR‐based interventions may serve as a practical foundation for future QI efforts, though their effectiveness may be influenced by factors such as uptake, flag fatigue, and ease of local workflow integration. The relationship between identified barriers and corresponding interventions can be more explicitly characterized using an implementation science‐informed framework [27]. Across studies, barriers clustered around three interrelated domains: (1) cognitive factors, including limited familiarity with bleeding disorders and competing clinical demands; (2) workflow and process factors, such as lack of standardized triage and ED treatment pathways; and (3) system‐level constraints, including limited access to patients’ medical history and access to haemostatic therapies. Interventions target these domains through distinct complementary mechanisms. EMR‐integrated order sets and clinical decision support tools aim to reduce cognitive burden and standardize decision‐making at point of care, while triage flags and prominently displayed individualized care plans help facilitate early recognition of high‐risk patients. Standardized ED care pathways and protocols are designed to address workflow fragmentation by streamlining processes and enabling earlier initiation of treatment. Educational initiatives were associated with high reported knowledge and confidence, reinforcing appropriate use of these tools. Together, these findings suggest that effective strategies align intervention components with specific underlying barriers, which often requires coordinated, multimodal approaches that operate across multiple levels of ED care. Several areas warrant further investigation. Although multiple studies reported reductions in time to haemostatic therapy following implementation of interventions, the clinical significance of these improvements remains uncertain. In many instances, post‐intervention times continued to exceed the recommended target of under 60 min, indicating that while process metrics improved, guideline‐concordant care was not consistently achieved. Moreover, it is unclear whether modest reductions in time to therapy translate into meaningful improvements in clinical outcomes, including bleeding‐related complications, repeat ED visits, hospitalization duration, functional outcomes, and mortality. Most studies did not assess clinically important endpoints such as bleeding‐related complications, length of hospitalization, repeat ED visits, morbidity, or mortality, particularly in relation to established time‐to‐treatment benchmarks. An exclusive focus on process metrics may therefore overestimate the effectiveness of interventions, as improvements in timeliness may not necessarily correspond to better clinical outcomes. Future research should prioritize the evaluation of important clinical outcomes to more accurately define the clinical impact of ED‐based interventions. In addition, few studies incorporated input from patients, caregivers, or HCPs in the design or evaluation of interventions, despite their central role as end users of ED‐based interventions. Greater engagement of these stakeholders would enhance the relevance, feasibility, and uptake of future interventions. Although improvements in process measures were reported in existing literature, low use of intervention‐related tools (such as EMR‐integrated ordersets) was sometimes reported. Reported barriers to uptake included alert fatigue, optional nature of some tools and pathways, and limited awareness amongst end users. Notably, many studies did not systematically report rates of adoption or evaluate challenges related to implementation, limiting interpretation of intervention fidelity and sustainability. These findings highlight the importance of incorporating stakeholder perspectives into QI efforts. Multidisciplinary QI teams can provide valuable insights into local workflows, feasibility, and contextual barriers, while also supporting dissemination and real‐time feedback during implementation. Such approaches may facilitate iterative refinement of interventions and improve their integration into routine clinical practice. The limitations of this scoping review relate to the inherent challenges of studying rare disorders. Given the rarity of bleeding disorders, most included studies were constrained by small sample sizes, making findings more susceptible to outliers and limiting generalizability. National and institutional variation in resources, policies, and bleeding disorders populations further reduce cross‐study comparability. Due to low numbers of studies, it was not possible to stratify results based on different parameters. Most studies were conducted exclusively in urban settings, with only a small number of national survey‐ or interview‐based studies including HCPs from rural areas, which may have limited identification of barriers specific to rural contexts. As haemophilia was the most commonly studied disorder, our results may not fully capture the unique considerations associated with other bleeding disorders. Almost all studies focused on congenital rather than acquired bleeding disorders; limited available data suggest that challenges related to recognition, diagnostic uncertainty, and access to appropriate therapies may be particularly relevant, but future investigation is needed to better characterize potential differences. Our inclusion criteria were also restricted to English language publications, potentially excluding relevant non‐English studies; however, only three studies were excluded on this basis. Additionally, the methodological quality of the included intervention studies limits causal inference. Most studies used pre‐post observational designs without randomization or controls, and interventions were typically implemented as a group of multimodal strategies. As a result, it is difficult to isolate the relative contribution of individual components, exclude the influence of unmeasured confounding factors, such as secular trends, concurrent initiatives, or changes in staffing and workflow. Ongoing research and knowledge translation are essential to advance ED care for people with bleeding disorders, ensure management aligns with established guidelines, evaluate the generalizability and sustainability of interventions, and determine long‐term impacts on patient outcomes. This review provides a comprehensive synthesis of the barriers and interventions to improve ED care, and offers a foundation for future QI research. These findings will also support multidisciplinary bleeding disorders care teams and ED HCPs in identifying and addressing barriers in their institutions, with the goal of improving outcomes for people with bleeding disorders worldwide. Author Contributions Ling‐Yi Guo and Kelsey Uminski conceived the review concept, with all authors contributing to the research questions and objectives. Ling‐Yi Guo, Diane L. Lorenzetti and Kelsey Uminski designed the search strategy. Ling‐Yi Guo and Kelsey Uminski screened articles and extracted data. Ling‐Yi Guo adrafted the initial manuscript. All authors reviewed, edited, and approved the final manuscript. Funding This work was supported by the Association of Hemophilia Clinic Directors of Canada Collaborative Hemostasis Initiative and Research Program. Disclosures Ling‐Yi Guo has received research grant from Association of Hemophilia Clinic Directors of Canada. Diane L. Lorenzetti has no disclosures. Natalia Rydz has received research funding from Novo Nordisk, consultancy fees from Pfizer, Sanofi, CSL Vifor and Vertex. Dawn Goodyear reports advisory boards and consultancy from Alexion, BioCryst, CSL Behring, Medison, Pfizer, Octapharma, Sanofi, Sobi, Roche and Takeda; research funding from Takeda. Julia Hews‐Girard has received unrestricted educational grants from CSL Behring (paid to institution) and research support (paid to institution) from Takeda. Garrick Mok has received speaking honorarium from Zoll Medical. Roy Khalife is supported by the Department of Medicine Meridith Marks Research Chair in Medical Education and declares research support from the Canadian Hemophilia Society and Association of Hemophilia Clinic Directors of Canada, as well as consultancy fees from CSL Behring, Novo Nordisk, Pfizer, Roche, Sanofi, and Takeda and speaker fees from Bayer, Pfizer, Sanofi, and Takeda. Kelsey Uminski has received educational grants from CSL Behring, Roche and Novo Nordisk, research funding from Bayer, Novo Nordisk and Pfizer, consultancy fees from Bayer, Biocryst Pharmaceuticals, Novo Nordisk, Roche, Sanofi and Takeda, speaker fees from Bayer, CSL Behring, Octapharma, Pfizer, Roche, Sanofi, and Takeda, and travel support from Novo Nordisk, Octapharma, Roche, and Sanofi. Ethics Statement This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors. Conflicts of Interest All authors report no conflicts of interests for this work.